摘要
目的：探讨哌罗匹隆联合脑电生物反馈治疗精神分裂症伴焦虑症状患者的临床疗效。方法将56例精神分裂症伴焦虑症状患者按随机数字表法分为两组，每组28例，均口服哌罗匹隆治疗，研究组联合脑电生物反馈治疗，观察6周。于治疗前后采用阳性与阴性症状量表评定精神症状，汉密顿焦虑量表评定焦虑状况。结果治疗2周末起两组阳性与阴性症状量表、汉密顿焦虑量表评分均较治疗前显著下降（P＜0．01），研究组治疗各时点评分均显著低于对照组（ P＜0．01）；治疗6周末研究组显效率为92．9％，对照组为71．4％，研究组显效率显著高于对照组（χ2＝4．38，P＜0．05）。结论哌罗匹隆联合脑电生物反馈治疗精神分裂症伴焦虑症状患者具有协同增效作用，起效快，疗效显著，优于单用哌罗匹隆治疗。
Objective To explore the clinical efficacy of perospirone plus EEG biofeedback therapy for schizophrenia with anxious symptoms .Methods Fifty‐six schizophrenia patients with anxious symptoms were randomly divided into two groups of 28 ones each ,both groups took orally perospirone ,and research group was plus EEG biofeedback therapy for 6 weeks .Mental symptoms were assessed with the Positive and Negative Syndrome Scale （PANSS） before and after treatment and anxious states with the Hamilton Anxiety Scale （HAMA） .Results Since the end of the 2nd week the PANSS and HAMA scores of both groups lowered more significantly compared with pretreatment （P〈0 .01） ,those at each time point were significantly lower in research than in control group （P〈0 .01）;at the end of the 6th week obvious effective rate was 92 .9% in research and 71 .4% in control group ,the former significantly higher than the latter （χ2 =4 .38 ,P〈0 .05） .Conclusion Perospirone plus EEG biological feedback therapy for schizophrenia has an synergism ,takes effect more rapidly ,and has an evident effect compared with single perospirone treat‐ment .
出处
《临床心身疾病杂志》
CAS
2016年第4期74-76,共3页
Journal of Clinical Psychosomatic Diseases
